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Summary Oral carcinogenesis is a multifactorial process involving numerous genetic events
that alter normal functions of oncogenes and tumor suppressor genes. It is well established that
an accumulation of genetic alterations is the basis for the progression from a normal cell to a
cancer cell, referred to as multi-step carcinogenesis. This event may be increased the production
of growth factors or the number of receptors on the cell surface, and/or increased transcription
factors or intracellular signal messengers, further that associated with deregulated control of cell
proliferation and apoptosis. Together with the loss of tumor suppressor activity, these changes
lead to a cell phenotype that can increase cell proliferation, with loss of cell cohesion, and
infiltration to adjacent tissue thus causing distant metastasis. Molecular medicine is responsible
for defining the molecular mechanisms that underlie the onset of oral cancer. This review focuses
on recent advances in our understanding of the molecular control of the innumerable pathways
related to these processes. These may lead to short- or medium term improvements in the
diagnosis and prognosis of oral cancerous lesions and to the development of novel therapeutic
approaches to this disease.
# 2011 Japanese Association for Dental Science. Published by Elsevier Ltd. All rights reserved.
* Corresponding author. Tel.: +81 49 285 5511x739; fax: +81 49 279 2745.
E-mail address: fukudam@dent.meikai.ac.jp (M. Fukuda).
a va i l a ble at ww w. sc ie nce di r ect . com
jo u rn al ho m epag e: ww w.els evier . c om / lo cat e/ jds r
1882-7616/$ — see front matter # 2011 Japanese Association for Dental Science. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.jdsr.2011.08.001
3.1. Tumor suppressor gene (Tables 1 and 2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.1.1. p53. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.1.2. p53R2 gene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.1.3. p33ING1b gene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.1.4. Cylindromatosis (CYLD) gene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4. Adhesion molecule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4.1. Neural cell adhesion molecule (NCAM) (Table 3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
5. Cytokines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
5.1. Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) (Tables 4a—4d) . . . . . . . . . . . . . . . . . . . . . 30
5.2. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): Has it gained the license to kill
tumor cells? (Table 5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
5.3. Interleukin (IL)-12 and IL-23 (Table 5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
5.4. Vascular endothelial growth factor (VEGF) (Table 5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
6. Transcriptional factor (Table 5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
6.1. Nuclear factor (NF)-kappaB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
6.2. Hypoxia inducible factor (HIF)-1alpha. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
7. As the other anti-cancer drugs: Has it potential of a novel lethal weapon against oral cancer? . . . . . . . . . . . . . . . 34
7.1. Cimetidine strikes back . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
8. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Acknowledgement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
24 M. Fukuda et al.1. Introduction
In recent years considerable progress has been made in
understanding the genetic basis of the development of
human oral squamous cell carcinoma (HOSCC). It is well
established that an accumulation of genetic alterations is
the basis for the progression from a normal cell to a cancer
cell, referred to as multi-step carcinogenesis [1]. Progression
is enabled by the increasingly more aberrant function of
genes that positively or negatively regulate aspects of pro-
liferation, apoptosis, genome stability, angiogenesis, inva-
sion and metastasis [2]. Gene function can be altered in
different ways: tumor suppressor genes may be inactivated
by mutation, deletion or methylation and oncogenes can be
activated by mutation or amplification. A description of these
alterations and how these are detected has previously been
described [3—5]. Oral cancers are characterized by a multi-
tude of these genetic alterations and ongoing research is
focusing on identifying the critical genetic events and the
order in which they occur during carcinogenesis. Frequently
occurring genomic alterations are supposed to contain the
genes that are the most important for the development of a
certain type of cancer [6]. Common alterations for oral
cancer are inactivation of TP53 (located at 17p13), gain of
chromosomal material at 3q26 and 11q13, and losses at 3p21,
13q21 and 14q32 [7,8]. For most of these regions the putative
tumor suppressor genes or oncogenes still need to be identi-
fied. In general, loss of chromosomal material (allelic losses)
at 3p, 9q and 17p was observed in a relatively high proportion
of dysplastic lesions and therefore these alterations were
interpreted to be early markers of carcinogenesis. Several
studies suggest, however, that early genetic changes do not
necessarily correlate with altered morphology.
Although recent improvements in the diagnosis and treat-
ment of malignant tumors have extended the average length
of patients’ lives, the incidence of multiple primary malig-
nant tumors is increasing [9]. In particular, it has beenreported that patients with head and neck cancer often
develop multiple primary neoplasms [10]. This phenomenon
has been attributed to ‘field cancerization’, a concept based
in the hypothesis that prolonged exposure to certain risk
factors, such as tobacco products, leads to the independent
transformation of multiple epithelial cells at several distinct
anatomic sites [11].
In addition, it is now becoming clear that the tumor
microenvironment, which is largely orchestrated by inflam-
matory cells, is an indispensable participant in the neoplastic
process, fostering proliferation, survival and migration.
Recent data have expanded the concept that tumor micro-
environments including hypoxia, and inflammation that are
the critical components of tumor progression. Many cancers
arise from sites of infection, chronic irritation and inflamma-
tion. Many tumors also contain hypoxic microenvironments, a
condition that is associated with poor prognosis and resis-
tance to treatment [12]. Thus, oral carcinogenesis is a highly
complex multifactorial process that takes place when epithe-
lial cells are affected by several genetic alterations. The use
of molecular biology techniques to diagnose oral cancerous
lesion might be markedly improved the detection of altera-
tions that are invisible under the microscope.
This review presents up-to-date evidence on molecular
markers that have shown promising results in evaluating the
efficacy of oral cancer treatments, with the potential to
markedly increase the patient survival rate.
2. Field cancerization
In 1953, Slaughter et al. [11] proposed the concept of field
cancerization to explain the strong tendency for patients who
are exposed repeatedly to carcinogenic factors such as
tobacco and alcohol, to develop multiple primary tumors.
These factors presumably increase the likelihood of devel-
oping multiple independent malignant foci in the mucosal
epithelium that is exposed to them.
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different stages. First, mucosal changes presumably occur in
the entire epithelial surface of the head and neck region.
These are considered to result from exposure to carcinogens
capable of causing multiple genetic abnormalities that
develop independently of each other throughout the entire
anatomic region [13]. After the initial event, 2 types of
migration might be involved in the further development of
the cancer: for example, there could be migration of tumor
cells by dissolution in saliva (micrometastases), or intrae-
pithelial migration of the progeny of the initially transformed
cells [13]. However, it is difficult to imagine that progenitor
cells with minimal genetic alterations have the capacity to
migrate intraepithelially over great distances, or that they
could become established elsewhere after displacement by
salivary flow. Indeed, it is known that small numbers of early
transformed cells that are surrounded by normal cells usually
do not succeed in developing into a new lesion. It is reported
that an increase in the proliferation rate in parabasal layers
of oral mucosal epithelia distant from an HOSCC is an indi-
cator of the risk of developing new tumors [14]. An aspect of
head and neck neoplastic development that is still unre-
solved, however, is the precise mechanism that underlies
the pathogenesis of multiple tumors in this region. Modern
molecular techniques may elucidate overall understanding of
the biology of these tumors, and ways to devise therapeutic
strategies to best manage these lesions, and thereby improve
prospects for survival [15,16].
3. Genetic alterations
3.1. Tumor suppressor gene (Tables 1 and 2)
Alterations of the p53 tumor suppressor gene are the most
frequently documented genetic abnormalities in human can-
cer, especially, oral squamous cell carcinomas. Therefore,
p53 gene and its related factors were selected in this section.
Cylindromatosis (CYLD) gene was nominated as a gene that
associated with adenoid cystic carcinoma, one of the typical
malignant salivary gland tumors.
3.1.1. p53
The p53 gene is a tumor suppressor that encodes a protein
with a molecular weight of 53 kDa that can arrest the cell
cycle at the late G1 phase in cells with sub-lethal damage in
their genome until their complete repair, or induce apoptosis
in cases of irreparable injury [17]. Among the genetic
changes involved, inactivation of the p53 tumor suppressor
gene by point mutation and allele loss is considered to be the
most common event underlying malignancies of every organ
[18]. These alterations also seem to be related to the multi-
step processes of oral carcinogenesis [19—23]. Mutations of
the p53 gene are dispersed over several hundred base pairs in
the midregion of the gene. They occur predominantly in
exons 5—8, which are hence known as hot regions [24,25],
and these mutations remain stable during metastasis [26].
Mutations of p53 must occur during early stages in the
development of head and neck SCCs because they are already
present in premalignant lesions [27]. Mutations of p53 gene
are not necessarily the critical, sole, nor the consistent
culprit in oral SCCs patients, however, between 30% and50% of SCCs of this region have been reported to harbor
p53 gene alterations [24,25,28]. By contrast, other markers
are less suitable due to their lack of stability, variability, or
difficulties with technical requirements for their detection.
The genes that occur high frequent alterations more than p53
have not been found so far. Furthermore, it has been
described that cancer with the mutated p53 gene is resistant
to radio-/chemotherapy and the patient has poor prognosis
than cancer patient with the wild-type p53 gene [29]. There-
fore, analysis of mutations in this particular gene gives a good
indication of clonal expansion of malignancies and important
prognostic information. Because the wild-type form of p53
has a half-life of only 6—30 min, the protein cannot be
generally detected by immunohistochemistry; however, if
the DNA is damaged, p53 protein accumulates and becomes
detectable [30]. So, to assess the frequency of p53 mutations
in HOSCCs and the correlations between p53 immunohisto-
chemical detections and p53 gene alterations, we examined
them by use of the formalin-fixed, paraffin-embedded speci-
mens from 40 patients with oral SCC treated in the Depart-
ment of Oral and Maxillofacial Surgery, Meikai University
Hospital, Saitama, Japan, from 1970 to 2001. Diagnosis of
oral lesions was based on histological examination of hema-
toxylin and eosin-stained slides. Of the 40 SCC patients, there
were 34 men and 6 women, whose ages ranged from 48 to 92
years, with a mean age of 66.2 years. A majority of the
patients were over 50 years of age. All specimens were
obtained from surgical biopsies that no patients had under-
gone chemotherapy or radiotherapy preoperatively. As the
results of immunohistochemistry using MAb p53 antibody, 22
of 40 cases (55%) were positive. Then the alterations in exons
5—8 of the p53 gene were analyzed by PCR-SSCP and direct
sequencing. The p53 point mutations were detected in 14 of
40 cases (35%) (Table 1). Similarly, a patient with multiple
primary carcinomas, including 4 separate cancers of the head
and neck region, which we previously reported [31], had no
correlations between p53 immunoreactivity and the detec-
tion of p53 gene alterations. These findings support those of
previous reports [32].
On the other hands, cancer development is principally
sporadic; however, since the concept of a constitutional
predisposition for neoplasia was suggested by Rokitansky
and Virchow [33], the occurrence of non-random clusters
of tumors has been recognized. Hereditary cancer syndromes
involving inherited gene mutations, such as Li-Fraumeni
syndrome, have also been described [33]. Li-Fraumeni syn-
drome is a rare familial multiple cancer syndrome associated
with germline p53 mutations and characterized by a striking
aggregation of multiple tumors of early onset. The familial
clustering in this syndrome is due to an inherited predisposi-
tion rather than environmental factors [34—37]. Li-Fraumeni
syndrome has been shown to involve a wide range of tumors,
including oral cancer. The condition predisposes patients to
an increased frequency of second primary cancers [33,38].
In general, functional inactivation of the p53 gene may be
an early event of carcinogenesis, and corresponding altera-
tion of p53 could contribute to oral carcinogenesis. There-
fore, evaluation of the p53 gene status should have clinical
value. A multidisciplinary treatment approach is also impor-
tant for maximizing functional ability and survival rates. It is
possible that multidisciplinary treatment, combined with
molecular analysis of the tumors, could offer molecular
Table 1 The correlations between p53, p53R2, p33ING1b expressions and clinicopathological variables in 40 cases of oral squamous cell carcinomas.
No. Age Gender Location Differentiation pTNM Stage Immunohistochemistry p53 gene alteration
p53 p53R2 p33ING1b
1 87 M Oral floor Well T2N2bM0 IVA + — — Exon 7 codon 258: GAA) CAA
Glu) Gln
2 48 F Gingiva Well T4N0M0 IVA — — — —
3 56 F Buccal mucosa Well T2N0M0 II — — — —
4 75 M Tongue Well T4N2cM0 IVA + + + Exon 7 codon 244: GGC) GGA
(silent)
5 55 M Oral floor Well T2N0M0 II — + + —
6 54 M Tongue Well T4N2bM0 IVA — — + —
7 54 M Oral floor Well T2N2aM0 IVA + — — —
8 70 M Tongue Well T2N0M0 II — — + Sequencing failed
9 67 M Maxillary gingiva Well T4N3M0 IVB 4+  — Exon 5 codon 151: CCC) CCA (silent)
10 92 M Soft palate Well T2N0M0 II + — — Sequencing failed
11 66 M Tongue Well T2N0M0 II + — — Exon 7 codon 244: GGC) AGC
Gly) Ser
12 87 M Tongue Well T2N0M0 II + — — Exon 5 codon 154: 1 bp insertion
(Frameshift)
13 48 F Tongue Well T1N0M0 I +  + —
14 85 M Tongue Well T2N1M0 III — — + —
15 56 F Tongue Well T1N2bM0 IVA —  + —
16 67 M Mandibular gingiva Well T1N2bM0 IVA + — + Sequencing failed
17 55 M Tongue Well T1N0M0 I — — + —
18 85 M Buccal mucosa Well T1N0M0 I + — — —
19 50 M Mandibular gingiva Well T3N1M0 III — + + —
20 67 M Mandibular gingiva Well T4N0M0 IVA + + + —
21 79 M Buccal mucosa Well T2N0M0 II + + + —
22 54 M Buccal mucosa Well T1N0M0 I — — + Exon 8 codon 282: C(T)GG
(insertion) (Arg) Trp)
23 54 M Mandibular gingiva Well T4N1M0 IVA + — + Not amplified
24 62 M Mandibular gingiva Well T1N0M0 I — — + Exon 8 codon 274: G(C)TT
(insertion) (Val) Leu)
25 60 M Maxillary gingiva Well T1N0M0 I + + + —
26 79 M Mandibular gingiva Moderately T4N2cM0 IVA 4+  — —
27 85 F Tongue Moderately T2N1M0 III — — + Not amplified
28 54 M Tongue Moderately T1N0M0 I + — — —
29 54 M Tongue Moderately T4N2bM0 IVA —  — Exon 8 codon 282: CGG) CGC (silent)
30 75 M Mandibular gingiva Moderately T1N0M0 I + — — —
31 66 F Mandibular gingiva Moderately T1N0M0 I 4+ — — —
32 65 M Mandibular gingiva Moderately T2N0M0 II — — — Exon 8 codon 274: GTT) GCT Val) Ala
33 88 M Mandibular gingiva moderately T2N0M0 II — + — Exon 8 codon 282: CGG) CGC (silent)
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tailored for the individual patient.
3.1.2. p53R2 gene
The p53 is thought to be involved in DNA repair by the
transcriptional activation of a ribonucleoside diphosphate
reductase (RR) gene, after exposure to genotoxic stresses
[39]. RR plays an essential role in converting ribonucleoside
diphosphate to 20-deoxyribonucleoside diphosphate. In an RR
holoenzyme, large a and small b subunits form an a2b2
heterotetramer that is required for RR activity [40]. In
humans, one large subunit (M1) and two small subunits
(hRRM2 and p53R2) of RR have been identified [39]. Two
RR small subunits, p53R2 and hRRM2, have an 80% similarity in
protein sequence, and the expression of hRRM2 is elevated at
the onset of the S-phase of the cell cycle [39]. However, only
p53R2 expression is induced by wild-type p53 in response to
various genotoxic stresses, including g-irradiation, UV-irra-
diation, or exposure to adriamycin, whereas expression of
hRRM2 occurred in a cell cycle-dependent manner and was in
fact suppressed in response to DNA damage [39]. It was
reported that DNA synthesis in cells arrested in G1 or G2
after DNA damage was mediated through the RR activity of
p53R2 and concluded that p53R2 might be directly involved in
processes designed to repair the damage [39]. A p53R2
translocates to the nucleus upon DNA damage, and subse-
quently, supplies an immediate pool of dNTPs necessary for
DNA repair. The p53R2 gene is localized on human chromo-
some 8q23.1 [39] and some investigators have suggested that
the genomic instability often seen in cancers lacking wild-
type p53 may reflect the dysfunction of RR due to the failure
of p53R2 induction [39,41,42]. In response to DNA damage,
p53R2, rather than hRRM2, was induced to facilitate DNA
repair in p53 wild-type cells [39,41,43]. However, hRRM2 can
complement the p53R2 function in response to UV irradiation
if p53 is dysfunctional [44]. A recent report suggested that
p53R2 had metastasis-suppressing ability in colon cancer, and
down-regulation of p53R2 by siRNA increased the invasion
potential of cancer cells [45].
The p53R2 is the latest RR subunit to be identified, and its
association with oral cancer cell invasive potential has not
yet been determined. Therefore, to determine whether the
p53R2 plays a role for DNA synthesis of HOSCC, we attempted
to investigate the correlation of p53R2 expression with oral
cancer invasion in vitro and in vivo and found that p53R2 was
negatively associated with the invasion of oral SCC [46]
(Table 1).
In conclusion, these findings suggested that the suppression
or damage of p53R2 function has occurred, and as the results,
the induction of apoptosis was inhibited at the invasive front
in early stage of HOSCC, regardless of p53 mutation.
3.1.3. p33ING1b gene
Inhibitor of growth, ING tumor-suppressor family proteins
(ING1—5) have been discovered during the past decade.
Especially, biological properties of ING1 suggested that it
was a negative growth regulator acting as a class II tumor
suppressor [47], playing a role in oncogenesis, apoptosis, DNA
repair, and cell cycle regulation [48,49]. Three alternatively
spliced transcripts of ING1 have been reported that encode
p47ING1a, p33ING1b, and p24ING1c [50—52]. The p33ING1b pro-
tein is the best-characterized and most widely expressed
28 M. Fukuda et al.isoform of the ING1 candidate tumor suppressor in human
normal tissues [50]. The ING1 proteins were frequently down-
regulated but less frequently mutated in human malignan-
cies, including neuroblastomas, colon carcinoma, head and
neck squamous cell carcinomas, breast, gastric, esophageal,
lymphoid, lung, and brain tumors, whereas they were
increased in melanoma, papillary thyroid carcinoma, and
ductal breast carcinoma, concomitant with loss of nuclear
localization [53—55]. Furthermore, ING1 protein has been
reported to bind directly to p53 protein by immunoprecipita-
tion in vitro, modulating the function of p53 as a transcrip-
tion activator [56]. ING1 gene is mapped on human
chromosome, 13q33—34, a region that has been implicated
in the progression of various tumors [57,58].
The p33ING1b has a close relationship with p53 and that
neither p53 nor p33ING1b alone can cause cell growth inhibi-
tion [56,59], which prompted us to investigate their potential
role in oral carcinogenesis. In our study, to determine
whether the p33ING1b isoform plays a role in chemosentivity
of HOSCC, we investigated the effect of p33ING1b overexpres-
sion on taxol-induced apoptosis and the activation of cas-
pases in HOSCC cells. Previous experimental evidences
indicated that the p33ING1b may cooperate with p53 in
taxol-induced apoptosis of the HOSCC. To test this hypoth-
esis, the HOSCC cell lines, contained wild-type p53 and
mutant p53, were employed to examine the enhancement
of apoptosis by p33ING1b overexpression and its mechanism. In
addition, the correlations between p53, p53R2, p33ING1b
expression and clinicopathological variables in HOSCC tissues
were examined immunohistochemically and summarized in
Table 1. It was not correlated between immunoreactivity for
p53, p53R2, p33ING1b and clinicopathological variables
though. It was suggested that the difference of these results
caused by the interference of the ubiquitin proteasomal
degradations.
In summary, our study demonstrated [60] that p33ING1b
enhanced taxol-induced apoptosis through p53-dependent
pathway in KB cells with p53 wild type of HOSCC. The over-
expression of p33ING1b promotes a chain reaction ultimately
leading to cell death through caspase-dependent apoptosis
pathway. The results suggest that p33ING1b plays a significant
role in the crucial tumor-suppressor pathways. As such,
p33ING1b may prove to be an important marker and/or ther-
apeutic target in the prevention and treatment of HOSCC.
3.1.4. Cylindromatosis (CYLD) gene
Molecular studies of familial and sporadic cylindromas, that
arise from the eccrine or apocrine cells of the skin [61,62],
have shown frequent alterations at chromosome 16q12—13,
recently found to house the cylindromatosis (CYLD) gene
[63—66]. CYLD, a tumor suppressor gene, has deubiquitinat-
ing enzyme activity and inhibits the activation of transcrip-
tion factor NF-kB [65,67—69], which has key roles in
inflammation, immune responses, tumorigenesis and protec-
tion against apoptosis [70—72]. In most cells, NF-kB is kept
inactive in the cytoplasm as a heterodimeric complex com-
posed of p50 and p65 (RelA) subunits bound to the inhibitory
protein, inhibitor of kB (IkBa) [73—75]. Insight into the
signaling mechanisms that lead to IkBa phosphorylation have
identified a high-molecular weight protein complex known
collectively as the IkB kinase (IKK) signalosome and including
IKKa, IKKb and IKKg also known as NF-kB essential modulator(NEMO) [76,77]. IKKa and IKKb have been identified as
catalytic subunits, whereas IKKg is a regulatory subunit
[76,78]. Generally, after stimulation by various reagents,
IkBa is phosphorylated at serine residues 32 and 36 by IKKa
and IKKb, together with the scaffold protein NEMO/IKKg [67—
69,79]. Serine phosphorylation results in polyubiquitination
of IkB and its subsequent degradation by the proteasome,
allowing NF-kB to translocate to the nucleus and activate its
target gene [71,79,80]. At this point, CYLD binds to NEMO/
IKKg and appears to regulate its activity through deubiqui-
tination of TRAF2 [68,69]. Therefore, loss of the deubiqui-
tinating activity of CYLD is correlated with tumorigenesis. It
has been reported that expression of CYLD is detectable in
brain, testis, skeletal muscle, spleen, liver, heart, lung and
leukocytes [65]. We have also demonstrated previously [81]
that the human salivary gland tumor cell line HSG, sponta-
neously expresses CYLD mRNA and protein.
Adenoid cystic carcinoma (ACC) is well known as a typical
malignant salivary gland tumor. Facial palsy caused by peri-
neural invasion of ACCs is particularly frequent. ACC was
previously referred to as cylindroma because of its remark-
able histologic resemblance to dermal cylindroma. We
further found that ACC arising from the hard palate was
distinctly positive for CYLD and NF-kB-related factors, immu-
nohistochemically [81]. However, it is unclear whether loss of
CYLD is associated with development of salivary gland
tumors. We attempted to examine the function of CYLD in
HSG cells. Furthermore, the expression and distribution of
CYLD, NF-kB and NF-kB-related factors were also investi-
gated in 17 cases of ACC, to elucidate whether CYLD is
associated with development of salivary gland tumors (Table
2). No correlations were detected between clinicopatholo-
gical variables and expression of CYLD or NF-kB-related
factors though.
Based on these in vitro and in vivo observations, one can
hypothesize that loss of CYLD function leads to NF-kB activa-
tion and subsequently anti-apoptosis, and that as a conse-
quence, it might be associated with tumorigenesis, including
growth, development and perineural invasion in human sali-
vary gland tumors, such as ACC [82].
4. Adhesion molecule
Cell adhesion molecules (CAMs) are found on the surfaces of all
cells, where they bind to extracellular matrix molecules or to
receptors on other cells. The expression of CAMs is normally
tightly regulated, thereby controlling cell proliferation, mobi-
lity, differentiation, and survival. Many of these processes are
misregulated in malignant tumors, and it has been shown that
many of the characteristics of tumor cells are attributable to
the aberrant expression or function of CAMs. New CAMS are
still being identified, and the families are becoming increas-
ingly complicated. At present, four main groups are described:
the integrins, cadherins, selectins, and the immunoglobulin
(Ig) superfamily [83]. A separate group includes molecules such
as CD44 which do not classify into any of the other specific
categories [83]. The role of CD44, which is also known as a
marker of stem cells in oral epithelial tumors, is uncertain in
keratinocytes. Splice variants of CD44 possibly involved in
migration and proliferation [83].
Here, we would like to introduce ‘neural cell adhesion
molecule’ which belongs in the Ig superfamily that associated
Table 2 The correlations between the expression of CYLD, NF-kB, IkBa, IKKa, IKKb and clinicopathological variables in 17 cases of
adenoid cystic carcinomas.
No. Age Gender Location TNM Stage CYLD NF-kB IkBa IKKa IKKb
1 58 F Oral floor T1N0M0 I + — + + —
2 62 F Sinus T2N1M0 III + — — + —
3 50 F Submandibular gland T2N0M0 II + — — + —
4 31 F Submandibular gland T3N1M0 IVA + — — + —
5 73 F Oral floor T2N0M0 II + — — + —
6 64 M Oral floor T2N0M0 II + ++ +++ +++ —
7 58 F Oral floor T3N0M0 III + ++ + ++ —
8 44 F Submandibular gland T3N0M0 III + ++ +++ + +
9 57 M Hard palate T1N0M0 I + ++ + ++ +
10 46 M Oral floor T2N0M0 II ++ + + + —
11 59 F Nasal cavity T2N0M0 II — ++ ++ ++ —
12 27 F Hard palate T2N1M0 III — + + + +
13 66 F Oral floor T4N3M0 IVB — + + — —
14 70 F Oral floor T2N0M0 II — + + — —
15 58 F Hard palate T4N1M0 IVA — + + — —
16 52 M Submandibular gland T1N0M0 I — ++ +++ + +
17 81 M Buccal mucosa T1N0M0 I — + ++ + —
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the typical malignant salivary gland tumors.
4.1. Neural cell adhesion molecule (NCAM)
(Table 3)
Neural cell adhesion molecule (NCAM) is a family of cell
surface glycoproteins and plays an important role in the
development of the nervous system, regulating cell migra-
tion, axonal outgrowth, branching, and fasciculation [84].
NCAM consists of several isoforms derived from alternative
splicing of one gene [85—87]. The three major isoforms with
molecular masses of 120,140 and 180 kDa have similar
extracellular parts, but differ in the disposition of their
domains, which are cytoplasmic for the two larger poly-
peptides [88,89]. Furthermore, NCAM expression is up-
regulated by transforming growth factor (TGF)-b [90—
92]. Although NCAM was initially described only in neural
tissue, it has also been found in human fetal muscle, kidney,
colon and lung as well as in elements of the hemopoietic
system. Moreover, it has been reported that NCAM is
expressed on a variety of human neoplasms and involved
in perineural invasions in various neoplasms, such as bile
duct cancer, gallbladder cancer, melanoma and adenoid
cystic carcinoma of the head and neck [93—98]. We also
demonstrated previously that NCAM is constitutively
expressed in human submandibular salivary gland tumor
cell line HSG, in vitro [99]. NCAM is considered to mediate
adhesion between cells through a Ca2+-independent homo-
philic (NCAM—NCAM) binding mechanism, and between
neurons and the extracellular matrix through heterophilic
binding (NCAM binding to another ligand or counter-recep-
tor) [84]. It has been shown that exogenously added NCAM
can inhibit the proliferation of cultured neonatal astrocytes
and astrocytes responding to a penetrating lesion in the
adult rat brain in vivo [100,101], suggesting that these
effects were mediated by homophilic binding to NCAM on
the astrocyte membrane.The ACCs are biologically aggressive and can give rise to
metastases many years after excision of the primary tumor.
Facial palsy is particularly frequent, causing perineural inva-
sion. However, it is still unclear whether NCAM is associated
with development in this type of salivary gland tumor. We
therefore attempted to treat HSG cells with MAb NCAM, in
vitro [102]. As shown in Fig. 1, these results imply that the
effect of MAb NCAM is specific to NCAM-expressing tumor
cells, such as HSG cells; furthermore, blocking the ability of
NCAM through MAb NCAM, as well as the homophilic (NCAM—
NCAM) binding mechanism, rather than regulating a signaling
pathway of cell proliferation, may in fact induce a negative
signal such as apoptosis in HSG cells. In addition, homophilic
(NCAM—NCAM) binding may activate multiple signaling path-
ways that differ among cell types [102]. Furthermore, the
expression and distribution of NCAM were also investigated in
13 cases of ACC, to elucidate whether NCAM is associated
with development of salivary gland tumors (Table 3).
As a conclusion of our study, it is suggested that NCAM
might be associated not only with a cell-to-cell adhesion
mechanism, but also with tumorigenesis, including growth,
development and perineural invasion in human salivary gland
tumors. Further studies will be required to identify the signal
transduction pathway utilized by glandular tumors after
treatment with MAb NCAM and to establish a strategy of
NCAM-based salivary gland tumor therapy.
5. Cytokines
Apoptosis, the process of programmed cell death, is known to
be not only necessary for the normal development and home-
ostasis of an organism, and to involve dramatic changes in
cellular structure, but also to provide a defense against
transformation and viral invasion [103,104]. The expression
of cytokines and their receptors in human neoplasms has
attracted a great deal of interest because of their potential
significance for tumor immunity. Members of the tumor
necrosis factor (TNF) cytokine family regulate the
Figure 1 Schematic representation of MAb NCAM-induced apoptotic signal transduction pathways via the DNA-damage signal through
the mitochondria involved in apaf-1 and caspase activation in NCAM-expressing cells.
30 M. Fukuda et al.elimination of unwanted immune cells by inducing apoptosis
[104]. Specifically, Fas (APO1/CD95) ligand (FasL) plays a key
role in peripheral deletion of self-reactive lymphocytes
[105]. Furthermore, TNF-related apoptosis-inducing ligand
(TRAIL) is a novel member of the TNF cytokine family that was
originally characterized by its ability to induce apoptosis
[106,107]. High expression of TRAIL in peripheral blood
leukocytes and in lymphoid tissues such as spleen and thymus
has led to the assumption that TRAIL might serve a similar
role to that of FasL in the control of peripheral immune
responses and in maintaining immune privilege [104]. How-
ever, despite their expression of these distinct antigens,
tumor elimination by the immune system is often inefficient.
Tumor cells may also evade immune attack by expressing
FasL, TRAIL or other molecules that induce apoptosis in
activated T cells [108]. We also observed in the previous
study that tumor cells possess a potential to escape immuneTable 3 The correlations between NCAM expression and clinicop
No. Age Gender Location 
1 73 F Oral floor 
2 57 M Soft palate 
3 46 M Oral floor 
4 64 M Oral floor 
5 31 F Submandibular gland
6 59 F Oral floor 
7 50 F Submandibular gland
8 58 F Hard palate 
9 62 F Maxillary sinus 
10 66 F Oral floor 
11 58 F Oral floor 
12 66 M Hard palate 
13 58 F Oral floor 
NCAM positive 9/13 cases = 69.2%.surveillance by killing host T lymphocytes through several
cytokines such as RCAS1 [109]. In the more recent study,
Interleukin (IL)-23 was identified as a cancer-associated
cytokine [110]. However, the precise role of IL-23 and its
function at the cancer invasive front is controversial.
5.1. Receptor-binding cancer antigen expressed
on SiSo cells (RCAS1) (Tables 4a—4d)
RCAS1 is a type II membrane protein isolated as a human
tumor-associated antigen by a mouse monoclonal antibody
(22-1-1 antibody) against a human uterine adenocarcinoma
cell line, SiSo [111]. RCAS1 acts as a ligand for a putative
receptor present on immune cells such as T, B and NK cells
and inhibits the growth of receptor-expressing cells, further
induces apoptotic cell death [108]. These observations sug-
gest a role of RCAS1 in the immune escape of tumor cells.athological variables in 13 cases of adenoid cystic carcinomas.
pTNM Stage NCAM expression
T2N0M0 II +
T1N0M0 I +
T2N0M0 II +
T2N0M0 II +
 T3N1M0 IV —
T2N0M0 II +
 T2N0M0 I +
T4N1M0 IVA —
T2N1M0 III +
T4N2bM0 IVA +
T1N0M0 I +
T3N0M0 III —
T3N0M0 III —
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[112—120] and were found to be positive for RCAS1 expres-
sion, no data exist as to whether RCAS1 is expressed in the
oral cancer.
We investigated whether RCAS1 is expressed in HOSCCs or
HOSCC cells and whether tumor cells which are expressing
RCAS1, induce apoptosis in its receptor-positive cells, PBLs.
The apoptotic index (AI) of TILs was also examined in HOSCC
tissues. The correlations between RCAS1 expressions and
clinicopathological variables in HOSCC and ACC tissues were
summarized in Tables 4a and 4b, and Tables 4c and 4d,
respectively. As the results, it was demonstrated that RCAS1
was frequently expressed both in HOSCC and ACC, in vitro
and in vivo, and its function on KB cells clearly led apoptosis
to PBLs in vitro [109]. Our results indicated that RCAS1
expression plays a key role in the immune escape mechanism
of oral cancer, thus that RCAS1 expression could be used as a
predictor of poor prognosis in patients with oral cancer.
Further investigation of the role of RCAS1 will be required
to clarify RCAS1-mediated tumor survival and to establish a
strategy of RCAS1-based oral cancer therapy.
5.2. Tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL): Has it gained the license
to kill tumor cells? (Table 5)
TRAIL, also called APO2 ligand (APO2L), is a novel member of
the TNF cytokine family that was originally characterized by
its ability to induce apoptosis [106,107]. It is known that
there are at least four closely related receptors which bind
TRAIL: death receptor-4 (DR4) and DR5/KILLER, which con-
tain cytoplasmic death domains and signal apoptosis
[106,107], and decoy receptor-1 (DcR1) [121—123] that lacks
a cytoplasmic tail and inhibits TRAIL function, further DcR2
[124,125], which contains a cytoplasmic region with a trun-
cated death domain that does not transduce the death signal
[125]. TRAIL interacts with its agonistic receptors DR4 and
DR5, inducing apoptosis in a variety of tumor cell lines
derived from malignant melanoma, lymphoma, colon carci-
noma, lung carcinoma, breast carcinoma, and malignant
gliomas [106,107,126,127]. Although DR4 is expressed in
many human normal cells and tissues, including spleen and
peripheral blood leukocytes, TRAIL induces apoptosis in var-
ious tumor cells but not in non-transformed, normal cells
[128]. This may be explained by the fact that TRAIL also
interacts with the antagonistic decoy receptors DcR1 and
DcR2, which are expressed in normal tissues but not in cancer
cells [122,123]. Neither DcR1 nor DcR2 receptors induce
apoptosis, but they protect cells from TRAIL-induced apop-
tosis [122—124]. To date, the biological relevance of the
complex TRAIL receptor system is unknown and conflicting
data exists. Nevertheless, because of its preferential cyto-
toxicity for cancer cells, TRAIL is regarded as a promising
anti-cancer weapon that might be highly effective in vivo
with few side effects as it has little or no lethal effect on
normal tissues.
TRAIL is expressed in most normal human cells and tissues,
including peripheral blood leukocytes, spleen, lung and pros-
tate, but not in the brain [107]. However, TRAIL expression in
human neoplasms was largely unknown. We investigated
whether TRAIL and its receptors are expressed in HOSCCsor HOSCC cell lines and whether these cell lines are sensitive
to TRAIL-induced apoptosis.
Our results [129] suggest their potential to escape immune
surveillance by killing host T lymphocytes via DR4/TRAIL and
DR5/TRAIL interactions, as suggested for Fas [130—132]. The
expression of decoy receptors in tumor cells was, however, a
phenomenon that contradicts previous reports [122,123].
Indeed, several authors have more recently reported that
a decoy receptor is also expressed in various tumor types, and
our result is consistent with their observations [133—135].
This fact suggests that tumor cells may evade TRAIL-induced
apoptosis by expressing a decoy receptor.
Generally, the most proximal step to suppress a death
receptor pathway is inhibition of ligand binding. This could be
achieved by lack of or mutations in death receptors
[136,137], or the presence of decoy receptors [123—126].
However, it has recently been mentioned by some investi-
gators that there is no correlation between TRAIL receptor
expression and susceptibility to TRAIL-induced apoptosis in
various tumor types [133—135]. Moreover, the existence of
anti-apoptotic proteins, such as bcl-2, bcl-xL and/or fas-like
IL-1 converting enzyme (FLICE)-like inhibitory protein
[138,139], also appears to be important due to their resis-
tance to death receptor mediated apoptosis. Collectively,
our results also suggested possibilities that there is no cor-
relation between TRAIL receptor expression and susceptibil-
ity to TRAIL-induced apoptosis in HOSCC cell lines, and that
TRAIL-resistant cells may express cytoprotective proteins
which block TRAIL-induced apoptosis, or that the apoptotic
effect of TRAIL is governed by other mechanisms.
It has also been reported that the combination of TRAIL
and an anti-cancer drug acted co-operatively to induce
apoptosis in various tumor cells which were resistant to TRAIL
or chemotherapy [133,140,141]. This TRAIL-based combina-
tion with chemotherapeutic agents might be a useful
approach for therapeutic strategies for TRAIL-resistant cells.
Further investigation of TRAIL-mediated apoptosis,
including the interaction of TRAIL and its receptors in oral
cancer cells under various conditions, will be required to
establish a strategy of TRAIL-based oral cancer therapy that
does not cause liver toxicity.
5.3. Interleukin (IL)-12 and IL-23 (Table 5)
The causal relationship between chronic inflammation,
innate immunity and cancer is now widely accepted, and
the similarities in the regulatory mechanisms have been
suggested for more than a century [142,143]. Many cancers
arise at the site of chronic inflammation and inflammatory
mediators are often produced in tumors [143,144]. The
frequent use of anti-inflammatory drugs reduces the inci-
dence of a variety of human tumors [145]. Although block-
ading some of these mediators has been shown to be
efficacious in experimental settings, it is still unclear
whether the inflammatory reaction at the tumor site pro-
motes tumor growth or simply implies the failed attempt of
the immune system to eliminate the rising malignancy.
IL-23, a heterodimeric cytokine with many similarities to
IL-12, has recently been identified as a factor linking tumor-
associated inflammation and a lack of tumor immune sur-
veillance [146]. IL-23 comprises a p19 subunit that associates
Table 4a The correlations between RCAS1 expression and clinicopathological variables in 40 cases of oral squamous cell
carcinomas.
No. Age Gender Location Differentiation pTNM Stage RCAS1 expression
1 87 M Oral floor Well T2N2bM0 IVA +
2 48 F Gingiva Well T4N0M0 IVA +
3 56 F Buccal mucosa Well T2N0M0 II —
4 75 M Tongue Well T4N2cM0 IVA +
5 55 M Oral floor Well T2N0M0 II —
6 54 M Tongue Well T4N2bM0 IVA ++
7 54 M Oral floor Well T2N2aM0 IVA +
8 70 M Tongue Well T2N0M0 II +
9 67 M Maxillary gingiva Well T4N3M0 IVB +
10 92 M Soft palate Well T2N0M0 II ++
11 66 M Tongue Well T2N0M0 II +
12 87 M Tongue Well T2N0M0 II +
13 48 F Tongue Well T1N0M0 I +
14 85 M Tongue Well T2N1M0 III +
15 56 F Tongue Well T1N2bM0 IVA +
16 67 M Mandibular gingiva Well T4N2bM0 IVA +
17 55 M Tongue Well T1N0M0 I ++
18 85 M Buccal mucosa Well T1N0M0 I +
19 50 M Mandibular gingiva Well T3N1M0 III ++
20 67 M Mandibular gingiva Well T4N0M0 IVA +
21 79 M Buccal mucosa Well T2N0M0 II +
22 54 M Buccal mucosa Well T1N0M0 I —
23 54 M Mandibular gingiva Well T4N1M0 IVA +
24 62 M Mandibular gingiva Well T1N0M0 I +
25 60 M Maxillary gingiva Well T1N0M0 I +
26 79 M Mandibular gingiva Moderately T4N2cM0 IVA +
27 85 F Tongue Moderately T2N1M0 III +
28 54 M Tongue Moderately T1N0M0 I —
29 54 M Tongue Moderately T4N2bM0 IVA +
30 75 M Mandibular gingiva Moderately T1N0M0 I +
31 66 F Mandibular gingiva Moderately T1N0M0 I —
32 65 M Mandibular gingiva Moderately T2N0M0 II —
33 88 M Mandibular gingiva Moderately T2N0M0 II +
34 79 M Mandibular gingiva Moderately T2N0M0 II +
35 54 M Buccal mucosa Moderately T2N0M0 II +
36 64 M Buccal mucosa Poorly T2N0M0 II +
37 62 M Tongue Poorly T2N1M0 III +
38 60 M Tongue Poorly T2N1M0 III —
39 60 M Tongue Poorly T1N0M0 I —
40 68 M Maxillary gingiva Poorly T3N0M0 III ++
RCAS1 positive 32/40 cases = 80%.
32 M. Fukuda et al.with the IL-12p40 subunit [110], whereas IL-12 is a combina-
tion of IL-12p35 and the same IL-12p40 subunit [147].
Although p19 is expressed in various tissues and cell types,
it lacks biological activity and only becomes biologically
active when complexed with p40, which is normally secreted
by activated macrophages and dendritic cells (DCs) [110]. IL-
23 uses many of the same signal-transduction components as
IL-12, including the IL-12 receptor (R) b1 subunit (IL-12Rb1),
Janus kinase (Jak)2, Tyk2, signal transducer and activator of
transcription (Stat)1, Stat3, Stat4, and Stat5 [110,148]. IL-
23R, composed of the IL-12Rb1 and the IL-23R subunit, is also
expressed in DCs, macrophages, and T cells [148]. Consistent
with the structural and biological similarities of IL-12 and IL-
23, the IL-23R complex shares a subunit with that of IL-12
(IL-12Rb1); however, it does not use or detectably bind toIL-12Rb2 [110]. The ability of cells to respond to either IL-12
or IL-23 is determined by expression of IL-12Rb2 or IL-23R,
respectively [148]. Additionally, both cytokines promote the
T helper cell type 1 (Th1) costimulatory function of antigen-
presenting cells [149]. However, IL-23 does differ from IL-12
in the Tcell subsets that it targets. IL-12 acts on naive CD4+ T
cells, whereas IL-23 preferentially acts on memory CD4+ T
cells [149]. It has been reported that IL-12 has potent anti-
tumor activity in a variety of murine tumor models, causing
regression of established tumors [150—152] and inhibiting the
formation of experimental metastases [150,151] and spon-
taneous metastases [153,154]. On the other hand, it has
recently been reported that genetic deletion or antibody-
mediated elimination of IL-23 in mice leads to increased
infiltration of cytotoxic T cells into the transformed tissue,
Table 4b The correlations between RCAS1 expression and tumor differentiation, pTNM, stage in 40 cases of oral squamous cell
carcinomas.
Variables RCAS1 expression p-value
Positive cases (%) Negative cases (%) Positive cases (%)
Tumor differentiation 0.2375
Well 22 (88) 3 (12)
Moderately 7 (70) 3 (30)
Poorly 3 (60) 2 (40)
pT (tumor size) 0.0495
T1—T2 21 (72.4) 8 (27.6)
T3—T4 11 (100) 0
pN (lymph node metastasis) 0.0529
N0 18 (72) 7 (28)
N+ 14 (93.3) 1 (6.7)
pM (distant metastasis) >0.9
M0 32 (80) 8 (20)
M1 0 0
pTNM stage 0.0267
Stage I—II 14 (66.7) 7 (33.3)
Stage III—IV 18 (94.7) 1 (5.3)
p-Values less than 0.05 were considered as significant.
Table 4c The correlations between RCAS1 expression and clinicopathological variables in 13 cases of adenoid cystic carcinomas.
No. Age Gender Location pTNM Stage RCAS1 expression
1 73 F Oral floor T2N0M0 II —
2 57 M Soft palate T1N0M0 I +
3 46 M Oral floor T2N0M0 II +
4 64 M Oral floor T2N0M0 II +
5 31 F Submandibular gland T3N1M0 IV +
6 59 F Oral floor T2N0M0 II +
7 50 F Submandibular gland T2N0M0 I +
8 58 F Hard palate T4N1M0 IVA +
9 62 F Maxillary sinus T2N1M0 III +
10 66 F Oral floor T4N2bM0 IVA +
11 58 F Oral floor T1N0M0 I —
12 66 M Hard palate T3N0M0 III +
13 58 F Oral floor T3N0M0 III +
RCAS1 positive 11/13 cases = 84.6%.
Table 4d The correlations between RCAS1 expression and clinicopathological variables in 13 cases of adenoid cystic carcinomas.
Variables RCAS1 expression p-value
Positive cases (%) Negative cases (%)
pT (depth of tumor invasion) 0.071
T1—T2 6 (75) 2 (25)
T3—T4 5 (100) 0
pN (lymph node metastasis) 0.0704
pN0 7 (77.8) 2 (22.2)
pN+ 4 (100) 0
pM (distant metastasis) >0.9
M0 11 (84.6) 2 (15.4)
M1 0 0
pTNM stage 0.0577
Stage I—II 5 (71.4) 2 (28.6)
Stage III—IV 6 (100) 0
p-Values less than 0.05 were considered as significant.
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carcinogenesis [146]. So far, it has been reported that expres-
sion of IL-23 and its receptors is detectable in activated
macrophages, DCs, and keratinocytes in healthy skin [155].
From our data [156,157], two separate lines of evidence
allowed us to conclude that IL-23 is a potent and specific
promoter of NF-kB activation in HSC-3 cells: (i) IL-23 pro-
moted nuclear transactivation of NF-kB, and (ii) IL-23
increased NF-kB dependent transcriptional activity. Further-
more, our in vivo studies also suggested that IL-23 might
promote NF-kB activity, alternatively IL-23 function might be
activated by NF-kB in SCC tissues [157] (Table 5). Finally, we
noted that IL-23 was secreted not only by DCs and macro-
phages, as shown in previous studies [147], but also by
autologous cancer cells. Consequently, we consider the exis-
tence of an autocrine mechanism, in which tumor growth is
promoted by IL-23 produced by autologous cancer cells. From
these combined data, we believe that IL-23 plays a significant
role in the growth and proliferation of oral cancer. Thus, IL-23
could be used as a predictor of poor prognosis in patients with
oral cancer, and its antibody might be able to use as an
inhibitor of oral cancer progression. Identification of the
signaling pathways underlying these events might provide
the key to elucidating the mechanism of development of oral
cancer. Further investigations into the role of IL-23 will be
required to fully understand IL-23-mediated tumor prolifera-
tion and to establish an IL-23-based oral cancer therapeutic
strategy.
5.4. Vascular endothelial growth factor (VEGF)
(Table 5)
Oral cancer is an important cause of worldwide morbidity and
mortality, with substantial economic, physiological, and psy-
chosocial impacts due to its treatment modality and a great
risk for recurrences and second primary OSCC development.
Therefore, it is very important to understand the underlying
cell biology of such tumors. It is now well-accepted fact that
angiogenesis is essential for the growth and metastasis of solid
tumors, including head and neck squamous cell carcinoma.
The main factor responsible for angiogenesis is VEGF and its
receptors [158]. It has been demonstrated that VEGFRs are also
present on tumor cells themselves and other cells from the
tumor microenvironment, in addition to tumoral endothelial
cells (ECs) [157]. Therefore between these cells take place
numerous and different interactions mediated via paracrine/
autocrine pathways that promote angiogenesis, uncontrolled
tumor proliferation and metastasation. In consequence, esti-
mation of VEGF expression and its receptors became a reliable
prognostic tool in OSCCS, predicting the poor disease-free
survival, poor overall survival, and metastatic disease. Under-
standing the distribution and role of VEGF and its receptors in
the progression of OSCC will be essential to the development
and design of new therapeutic strategies.
6. Transcriptional factor (Table 5)
The ancient stress response is the innate immune response,
regulated by several transcription factors, among which NF-
kappaBplaysacentral role.Thehypoxicresponseisalsoancient
stress response triggered by low ambient oxygen (O2) andcontrolled by hypoxia inducible transcription factor-1, whose
a subunit is rapidly degraded under normoxia but stabilized
when O2-dependent prolylhydroxylases (PHDs) that target its
O2-dependent degradation domain are inhibited. Thus, the
amount of HIF-1alpha, which controls genes involved in energy
metabolism and angiogenesis, is regulatedpost-translationally.
So, NF-kappaB and hypoxia-inducible factor-1 were selected
as the typical transcriptional factors in this section.
6.1. Nuclear factor (NF)-kappaB
Nuclear factor-kB (NF-kB) has key roles in inflammation,
immune response, tumorigenesis and protection against
apoptosis [70—72]. A detailed discussion of NF-kB can be
found in Section 3.1.4.
6.2. Hypoxia inducible factor (HIF)-1alpha
Protection against hypoxia in solid tumors is an important
step in tumor development and progression. One system in
hypoxia protection of tumor cells is represented by the
hypoxia-inducible factor 1 (HIF-1) system which plays a
crucial role in biologic processes under hypoxic conditions,
especially in angiogenesis and carcinogenesis [159,160].
HIF-1 is a heterodimer, composed of HIF-1a (120 kDa) and
HIF-1b (91, 93, 94 kDa) [161]. HIF-1a subunit, is a transcription
factor in response to cellular hypoxia, plays an important role
in tumor growth and metastasis by regulating energy meta-
bolism and inducing angiogenesis [162]. However, under nor-
moxic conditions, HIF-1a is maintained at low levels due to
continuous degradation via the ubiquitin-dependent proteo-
some pathway, and this pathway is inhibited by hypoxia and by
p53 or von Hippel-Lindau tumor-suppressor gene defects,
leading to stabilization of the HIF-1a protein [163—166].
Therefore, hypoxia can lead to a rapid increase in HIF-1a
protein levels [163,166—168]. Furthermore, HIF-1a up-regu-
lates a number of important factors for tumor expansion,
including VEGF, a key factor in tumor angiogenesis [169—
171]. In several cancers, overexpression of HIF-1a protein
has been found to be associated with tumor aggressiveness
and with an unfavorable prognosis [159,172,173]. Hypoxia has
also been reported to induce wild-type p53 via a different
pathway than DNA-damaging agents [174]. The hypoxic/
anoxic induction of p53 selects for tumor cells that lack
functional p53, and hence evidence diminished apoptotic
potential [175]. Elevated levels of HIF-1a are noted in various
malignant tumors [159], but it is unclear whether this is so in
oral carcinoma. Therefore, we have examined the implica-
tions of HIF-1a expression in HOSCC, in vitro and in vivo.
NanoCulture plate system was used to duplicate hypoxic con-
dition within tumor mass of living organisms by the three-
dimensional cell culture. As the results, we found that HIF-1a
regulates the expression of VEGF, and that HIF-1a may be
regulated by p53 in SCC of the oral cavity [176] (Table 5).
7. As the other anti-cancer drugs: Has it
potential of a novel lethal weapon against
oral cancer?
Although there are numerous anti-cancer drugs, here, we
would daringly like to propose the anti-cancer effect of
Table 5 The correlations between the expression of p53, TRAIL, IL-23, VEGF, NF-kB, HIF-lcx and clinicopathological variables in 40
cases of oral squamous cell carcinomas.
No. Age Gender Location Differentiation pTNM Stage Immunohistochemistry
p53 TRAIL IL-23 VEGF NF-kB HIF-la
1 87 M Oral floor Well T2N2bM0 IVA + + +  + 
2 48 F Gingiva Well T4N0M0 IVA — — —  + +
3 56 F Buccal mucosa Well T2N0M0 II — — —  + 
4 75 M Tongue Well T4N2cM0 IVA + — +  + +
5 55 M Oral floor Well T2N0M0 II — — + + + —
6 54 M Tongue Well T4N2bM0 IVA — — — + + +
7 54 M Oral floor Well T2N2aM0 IVA + — — + + —
8 70 M Tongue Well T2N0M0 II — — — + + —
9 67 M Maxillary gingiva Well T4N3M0 IVB 4+ — — — + —
10 92 M Soft palate Well T2N0M0 II + — —  — ++
11 66 M Tongue Well T2N0M0 II + — —  + +
12 87 M Tongue Well T2N0M0 II + — —  — —
13 48 F Tongue Well T1N0M0 I + + — ++ — 
14 85 M Tongue Well T2N1M0 III — + + + — —
15 56 F Tongue Well T1N2bM0 IVA — + — ++ + ++
16 67 M Mandibular gingiva Well T1N2bM0 IVA + — + + + ++
17 55 M Tongue Well T1N0M0 I — — + ++ + +
18 85 M Buccal mucosa Well T1N0M0 I + + + + — +
19 50 M Mandibular gingiva Well T3N1M0 III — + + ++ + +
20 67 M Mandibular gingiva Well T4N0M0 IVA + — + + + ++
21 79 M Buccal mucosa Well T2N0M0 II + — + + + ++
22 54 M Buccal mucosa Well T1N0M0 I — + — ++ + ++
23 54 M Mandibular gingiva Well T4N1M0 IVA + — —  — ++
24 62 M Mandibular gingiva Well T1N0M0 I — — + + + +
25 60 M Maxillary gingiva Well T1N0M0 I + — + ++ — +
26 79 M Mandibular gingiva Moderately T4N2cM0 IVA 4+ — — — + ++
27 85 F Tongue Moderately T2N1M0 III — + —  + ++
28 54 M Tongue Moderately T1N0M0 I + — —  + +
29 54 M Tongue Moderately T4N2bM0 IVA — + —  + ++
30 75 M Mandibular gingiva Moderately T1N0M0 I + — —  — 
31 66 F Mandibular gingiva Moderately T1N0M0 I 4+ + —  — 
32 65 M Mandibular gingiva Moderately T2N0M0 II — — — — — +
33 88 M Mandibular gingiva Moderately T2N0M0 II — — — + + +
34 79 M Mandibular gingiva Moderately T2N0M0 II + + — ++ + +
35 54 M Buccal mucosa Moderately T2N0M0 II — — + ++ + —
36 64 M Buccal mucosa Poorly T2N0M0 II 4+ — — — + +
37 62 M Tongue Poorly T2N1M0 III + — — — + ++
38 60 M Tongue Poorly T2N1M0 III — — —  + ++
39 60 M Tongue Poorly T1N0M0 I + — — + + +
40 68 M M. gingiva Poorly T3N0M0 III — — +  + —
P53 expression: 22/40 (55%); TRAIL expression: 11/40 (27.5%); IL-23 expression: 14/40 (35%); VEGF expression 35/40 cases (87.5%); NF-kB
expression 30/40 (75%); HIF-la expression: 32/40 (80%).
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just a stomach medicine, and it is free of side effects such as
that the other anti-cancer drugs have. Furthermore, H2R
blockers are comprised of cimetidine, famotidine, and rani-
tidine, however, it is reported that only cimetidine has a
precise effect as the anti-cancer drug.
In addition, although malignant glandular tumors are
known to be generally resistant to radiation therapy and
chemotherapy, the efficacy of cimetidine is observed occa-
sionally in the clinical application for glandular tumor. There-
fore, if cimetidine has an effect of anti-cancer drug for oral
cancer, it will be ideal drug in this lesion.7.1. Cimetidine strikes back
Cimetidine, the oldest histamine type-2 receptor (H2R)
antagonist to be used clinically, is commonly prescribed
to treat gastro-esophageal reflux disease as well as gastric
and duodenal ulcers [177]. Although it is like a half-remem-
bered drug, it has recently been reported that cimetidine
improves the survival of patients with malignant tumors
[178,179], including gastric [180] and colorectal carcino-
mas [181]. Cimetidine has been shown to inhibit growth of
gastrointestinal cancers via several mechanisms including
enhancement of immune activity and inhibition of cancer
36 M. Fukuda et al.cell proliferation [179]. Therefore cimetidine may act by
enhancing the host immune response against tumor cells
[182,183] or by blocking the cell growth-promoting activity
of histamine [183—188]. Kobayashi et al. [187] reported
that cimetidine inhibits colon adenocarcinoma cell adhe-
sion to vascular endothelial cells and prevents metastasis
by blocking E-selectin expression. We also demonstrated
recently that cimetidine inhibited neural cell adhesion
molecule (NCAM) expression and induced apoptosis in
salivary gland tumor cells [188]. However, the exact
mechanisms by which cimetidine suppresses the develop-
ment of salivary gland tumors remain to be elucidated.
ACC is a well known and typical malignant salivary gland
tumor. Facial paralysis due to perineural/neural invasion
occurs so frequently that it is generally accepted as a
hallmark of ACCs [98—100], and inhibition of perineural/
neural invasion could be a strategy for arresting the devel-
opment of ACC.
Then, we have examined the effect of cimetidine on
cancer cell adhesion to neural cells in vitro, one of the
critical steps of cancer invasion and metastasis. We have
also used an in vivo carcinogenesis model to confirm the
effect of cimetidine. We demonstrated previously [99] that
NCAM is spontaneously expressed in HSG cells and that HSG
cell proliferation may be controlled via a homophilic
(NCAM—NCAM) binding mechanism. We have also shown
that NCAM may be involved in perineural/neural invasion
by malignant salivary gland tumors [102]. Furthermore, it
has been reported that NCAM expression is regulated by
NF-kB and that NF-kB activity is induced by homophilic
NCAM binding [189,190]. In conclusion, our experiments
clearly demonstrated that cimetidine effectively down-
regulates the induction of NCAM by inhibiting the trans-
activation of NF-kB, which subsequently blocks HSG
adhesion to neural cells, and ultimately induces apoptosis
in HSG cells and prevents the growth of HSG tumor
masses in nude mice in which the salivary gland tumor
cell line HSG was injected subcutaneously [191]. These
findings may explain clinical observations by several
authors [178,179] that cimetidine improves the survival
of patients with malignant tumors. Although malignant
glandular tumors are known to be generally resistant to
radiation therapy and chemotherapy, the clinical applica-
tion of cimetidine as an anti-cancer drug might form an
integral part of future therapeutic strategies against
NCAM-expressing tumors such as adenoid cystic carcinoma.
Further studies will be required to identify the signal
transduction pathways by which treatment with cimetidine
suppresses the growth of glandular tumors and to establish
a strategy for cimetidine-based therapy of salivary gland
tumors.
8. Conclusion
Despite major advances in the molecular medicine of oral
cancer, there remain numerous gaps in our knowledge of the
molecular markers involved in oral carcinogenesis. HOSCCs
appear to have a multifocal character, with only half of them
developing on the same site as a previous leukoplakia.
Complex molecular mechanisms are implicated and the
identification of a single marker to predict outcomes in alloral premalignant lesions remains a difficult challenge.
Among reported markers are for inactivation of tumor sup-
pressor genes, notably p53, p53R2, p33ING1b and CYLD. Their
study may contribute to the search for reliable molecular
markers of the development of oral cancer. Other molecular
medicine approaches are emerging, including assessment of
the promoter regions of certain genes (e.g. NCAM, RCAS1 and
IL-23) or tumor—stroma interactions, which could provide
new and promising data. However, it is clear that further
study is essential to be used as effective diagnostic and
prognostic markers to improve the management of oral
cancer patients.
Furthermore, despite advances in detection and medical
therapy of oral cancer, mortality of this disease remains
high because current therapies are limited by the emer-
gence of therapy-resistant cancer cells, termed oral cancer
stem cells (CSCs). CSCs have recently attracted a great deal
of interest. The characteristics of CSCs include an ability to
proliferate (self-replication capacity) and to differentiate
into several cell types with different functions (multidif-
ferentiation capacity), as well as a tumorigenic capacity.
However, little is known about the oral CSCs function. It has
been described that head and neck cancer indeed follows
the CSC hypothesis, since implantation of few cells con-
sistently gives rise to tumors that can be serially passaged
in vivo [192]. Therefore, further researches will be
required to elucidate the functional interactions between
oral CSCs and surrounding stromal cells and to establish a
strategy for CSCs-targeted therapy of oral cancer in the
near future.
Conflict of interest
There are no financial and personal relationships with other
people or organizations that could inappropriately influence
this review article.
Acknowledgement
This work was supported in part by a Grant-in-Aid for scien-
tific research from the Ministry of Education, Science, and
Culture of Japan.
References
[1] Califano J, van der Riet P, Westra W, Nawroz H, Clayman G,
Piantadosi G, et al. Genetic progression model for head and
neck cancer: implications for field cancerization. Cancer Res
1996;56:2488—92.
[2] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;
100:57—70.
[3] van Houten VM, Tabor MP, van den Brekel MW, Denkers F,
Wishaupt RG, Kummer JA, et al. Molecular assays for the
diagnosis of minimal residual head-and-neck cancer: meth-
ods, reliability, pitfalls, and solutions. Clin Cancer Res
2000;6: 3803—16.
[4] Reid CB, Snow GB, Brakenhoff RH, Braakhuis BJ. Biologic
implications of genetic changes in head and neck squamous
cell carcinogenesis. Aust N Z J Surg 1997;67:410—6.
[5] Braakhuis BJM, Tabor MP, Leemans CR, van der Waal I, Snow GB,
Brakenhoff RH. Second primary tumors and field cancerization
in oral and oropharyngeal cancer: molecular techniques
The proliferation and progression mechanisms of the oral cancer 37provide new insights and definitions. Head Neck 2002;24:
198—206.
[6] Albertson DG, Collins C, Mccormick F, Gray JW. Chromosome
aberrations in solid tumors. Nat Genet 2003;34:369—76.
[7] Gollin SM. Chromosomal alterations in squamous cell carcino-
mas of the head and neck: window to the biology of disease.
Head Neck 2001;23:238—53.
[8] Forastiere A, Koch W, Trotti A, Sidransky D. Medical progress—
head and neck cancer. N Engl J Med 2001;345:1890—900.
[9] Licciardello JT, Spitz MR, Hong WK. Multiple primary cancer in
patients with cancer of the head and neck: second cancer of
the head and neck, esophagus, and lung. Int J Radiat Oncol Biol
Phys 1989;17:467—76.
[10] Sakashita H, Miyata M, Miyamoto H, Kurumaya H. A case of
quadruple cancer, including triple cancers in the head and neck
region. J Oral Maxillofac Surg 1996;54:501—5.
[11] Slaughter DP, Southwick HW, Smejkal W. Field cancerization in
oral stratified squamous epithelium; clinical implications of
multicentric origin. Cancer 1953;6:963—8.
[12] Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and
pO2 gradients in solid tumors in vivo: high-resolution measure-
ments reveal a lack of correlation. Nature Med 1997;3:177—82.
[13] van Oijen MG, Slootweg PJ. Oral field cancerization: carcino-
gen-induced independent events or micrometastatic deposits?
Cancer Epidemiol Biomarkers Prev 2000;9:249—56.
[14] Gonza´lez-Moles MA, Bravo M, Ruiz-A´vila I, Acebal F, Gil-Mon-
toya JA, Brener S, et al. Ki-67 expression in non-tumour
epithelium adjacent to oral cancer as risk marker for multiple
oral tumours. Oral Dis 2010;16:68—75.
[15] Gluckman JL, Crissman JD. Survival rates in 548 patients with
multiple neoplasms of the upper aerodigestive tract. Laryngo-
scope 1983;93:71—4.
[16] Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA,
et al. Second malignancies in patients who have head and neck
cancer: incidence, effect on survival and implications based
on the ROTG experience. Int J Radiat Oncol Biol Phys 1989;17:
449—56.
[17] Cordon-Cardo C. Mutation of cell cycle regulators. Biological
and clinical implications for human neoplasia. Am J Pathol
1995;147:545—60.
[18] Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 muta-
tions in human cancers. Science 1991;253:49—53.
[19] Warnakulasuriya KA, Johnson NW. Expression of p53 mutant
nuclear phosphoprotein in oral carcinoma and potentially
malignant oral lesions. J Oral Pathol Med 1992;21:404—8.
[20] Kusama K, Okutsu S, Takeda A, Himiya T, Kojima A, Kidokoro Y,
et al. p53 gene alterations and p53 protein in oral epithelial
dysplasia and squamous cell carcinoma. J Pathol 1996;178:
415—21.
[21] Crosthwaite N, Teale D, Franklin C, Foster GA. Stringer B. p53
protein expression in malignant, premalignant and non-malig-
nant lesions of the lip. J Clin Pathol 1996;49:648—53.
[22] Stoll C, Baretton G, Lohrs U. The influence of p53 and associ-
ated factors on the outcome of patients with oral squamous
cell carcinoma. Virchows Arch 1998;433:427—33.
[23] Gulley ML, Burton MP, Allred DC, Nicholls JM, Amin MB, Ro JY,
et al. Epstein-Barr virus infection is associated with p53 accu-
mulation in nasopharyngeal carcinoma. Hum Pathol 1998;29:
252—9.
[24] Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL,
Casey G. Frequent p53 mutations in head and neck cancer.
Cancer Res 1992;52:5997—6000.
[25] Caamano J, Zhang SY, Rosvold EA, Bauer B, Klein-Szanto AJ.
p53 alterations in human squamous cell carcinomas and carci-
noma cell lines. Am J Pathol 1993;142:1131—9.
[26] Tjebbes GW, Leppers VD, Straat FG, Tilanus MG, Hordijk GJ,
Slootweg PJ. p53 tumor suppressor gene as a clonal marker in
head and neck squamous cell carcinoma: p53 mutations inprimary tumor and matched lymph node metastases. Oral
Oncol 1999;35:384—9.
[27] Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK, et al.
Activation of p53 gene expression in premalignant lesions
during head and neck tumorigenesis. Cancer Res 1994;
54:321—6.
[28] Nylander K, Dabelsteen E, Hall PA. The p53 molecule and its
prognostic role in squamous cell carcinomas of the head and
neck. J Oral Pathol Med 2000;29:413—25.
[29] Obata A, Eura M, Sasaki J, Saya H, Chikamatsu K, Tada M, et al.
Clinical significance of p53 functional loss in squamous cell
carcinoma of the oropharynx. Int J Cancer 2000;89:187—93.
[30] Langdon JD, Partridge M. Expression of the tumor suppressor
gene p53 in oral cancer. Br J Oral Maxillofac Surg 1992;30:
214—20.
[31] Fukuda M, Nakatsuka T, Kusama K, Sakashita H. Patient with
multiple primary carcinomas, including four separate oral
cancers: study of p53 mutations and their implications for
management. J Oral Maxillofac Surg 2006;64(11):1672—9.
[32] Ka¨rja¨ VJ, Syrja¨nen KJ, Kurvinen A-K, Syrja¨nen SM. Expression
and mutations of p53 in salivary gland tumors. J Oral Pathol
Med 1997;26:217—23.
[33] Patrikidou A, Bennett J, Abou-Sleiman P, Delhanty JD, Harris M.
A novel, de novo germline TP53 mutation in a rare presentation
of the Li-Fraumeni syndrome in the maxilla. Oral Oncol
2002;38:383—90.
[34] Li FP, Fraumeni Jr JF. Rhabdomyosarcoma in children: epide-
miologic study and identification of a familial cancer syn-
drome. J Natl Cancer Inst 1969;43:1365—73.
[35] Li FP, Fraumeni Jr JF. Soft-tissue sarcomas, breast cancer, and
other neoplasms. A familial syndrome? Ann Intern Med 1969;
71:747—52.
[36] Birch JM, Hartley AL, Blair V, Kelsey AM, Harris M, Teare MD,
et al. Cancer in the families of children with soft tissue
sarcoma. Cancer 1990;66:2239—48.
[37] Strong LC, Stine M, Norsted TL. Cancer in survivors of child-
hood soft tissue sarcoma and their relatives. J Natl Cancer Inst
1987;79:1213—20.
[38] Li FP, Fraumeni Jr JF. Prospective study of a family cancer
syndrome. JAMA 1982;247:2692—4.
[39] Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S,
Matsui K, et al. A ribonucleotide reductase gene involved in a
p53-dependent cell-cycle checkpoint for DNA damage. Nature
2000;404:42—9.
[40] Jordan A, Reichard P. Ribonucleotide reductases. Annu Rev
Biochem 1998;67:71—98.
[41] Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA,
Nakamura Y, et al. P53R2-dependent pathway for DNA synthe-
sis in a p53-regulated cell cycle checkpoint. Cancer Res
2001;61:8256—62.
[42] Byun DS, Chae KS, Ryu BK, Lee MG, Expression CHISG. mutation
analyses of p53R2, a newly identified p53 target for DNA repair
in human gastric carcinoma. Int J Cancer 2002;98:718—23.
[43] Nakano K, Ba´lint E, Ashcroft M, Vousden KH. A ribonucleotide
reductase gene is a transcriptional target of p53 and p73.
Oncogene 2000;19:4283—9.
[44] Zhou B, Liu X, Mo X, Xue L, Darwish D, Qiu W, et al. The human
ribonucleotide reductase subunit hRRM2 complements p53R2
in response to UV-induced DNA repair in cells with mutant p53.
Cancer Res 2003;63:6583—94.
[45] Liu X, Zhou B, Xue L, Shih J, Tye K, Lin W, et al. Metastasis-
suppressing potential of ribonucleotide reductase small sub-
unit p53R2 in human cancer cells. Clin Cancer Res 2006;12:
6337—44.
[46] Fukuda M, Inoue K, Sugawara Y, Yagishita H, Sakashita H.
Implication of p53R2 disappearance in human squamous cell
carcinoma of the oral cavity. Hosp Dent (Tokyo) 2010;22(1):
3—8.
38 M. Fukuda et al.[47] Sager R. Expression genetics in cancer: shifting the focus from
DNA to RNA. Proc Natl Acad Sci USA 1997;94:952—5.
[48] Helbing CC, Veillette C, Riabowol K, Johnston RN, Garkavtsev
I. A novel candidate tumor suppressor, ING1, is involved in the
regulation of apoptosis. Cancer Res 1997;57:1255—8.
[49] Garkavtsev I, Riabowol K. Extension of the replicative life span
of human diploid fibroblasts by inhibition of the p33ING1
candidate tumor suppressor. Mol Cell Biol 1997;17:2014—9.
[50] Garkavtsev I, Kazarov A, Gudkov A, Riabowol K. Suppression of
the novel growth inhibitor p33ING1 promotes neoplastic trans-
formation. Nat Genet 1996;14:415—20.
[51] Gunduz M, Ouchida M, Fukushima K, Hanafusa H, Etani T,
Nishioka S, et al. Genomic structure of the human ING1 gene
and tumor-specific mutations detected in head and neck
squamous cell carcinomas. Cancer Res 2000;60:3143—6.
[52] Saito A, Furukawa T, Fukushige S, Koyama S, Hoshi M,
Hayashi Y, et al. p24/ING1-ALT1 and p47/ING1-ALT2, distinct
alternative transcripts of p33/ING1. J Hum Genet 2000;
45:177—81.
[53] Gong W, Suzuki K, Russell M, Riabowol K. Function of the ING
family of PHD proteins in cancer. Int J Biochem Cell Biol
2005;37:1054—65.
[54] Takahashi M, Ozaki T, Todo S, Nakagawara A. Decreased ex-
pression of the candidate tumor suppressor gene ING1 is
associated with poor prognosis in advanced neuroblastomas.
Oncol Rep 2004;12:811—6.
[55] Yu GZ, Zhu MH, Zhu Z, Ni CR, Zheng JM, Li FM. Genetic
alterations and reduced expression of tumor suppressor
p33(ING1b) in human exocrine pancreatic carcinoma. World
J Gastroenterol 2004;10:3597—601.
[56] Garkavtsev I, Grigorian IA, Ossovskaya VS, Chernov MV, Chu-
makov PM, Gudkov AV. The candidate tumour suppressor
p33ING1 cooperates with p53 in cell growth control. Nature
1998;391: 295—8.
[57] Zeremski M, Horrigan SK, Grigorian IA, Westbrook CA, Gudkov
AV. Localization of the candidate tumor suppressor gene ING1
to human chromosome 13q34. Somat Cell Mol Genet 1997;23:
233—6.
[58] Garkavtsev I, Demetrick D, Riabowol K. Cellular localization
and chromosome mapping of a novel candidate tumor suppres-
sor gene (ING1). Cytogenet Cell Genet 1997;76:176—8.
[59] Vieyra D, Toyama T, Hara Y, Boland D, Johnston R, Riabowol K.
ING1 isoforms differentially affect apoptosis in a cell age-
dependent manner. Cancer Res 2002;62:4445—52.
[60] Fukuda M, Sakashita H. Tumor suppressor p33ING1b enhances
taxol-induced apoptosis in human squamous cell carcinoma of
the oral cavity. Hosp Dent (Tokyo) 2010;21(2):91—6.
[61] Lever W, Schaumburg-Lever G. Histopathology of the skin, 7th
ed., Philadelphia: Lippincott, JB; 1990. pp. 848—851.
[62] Tellechea O, Reis JP, Ilheu O, Baptista AP. Dermal cylindroma.
An immunohistochemical study of thirteen cases. Am J Der-
matopathol 1995;17:260—5.
[63] Biggs PJ, Wooster R, Ford D, Chapman P, Mangion J, Quirk Y,
et al. Familial cylindromatosis (turban tumour syndrome) gene
localised to chromosome 16q12—q13: evidence for its role as a
tumour suppressor gene. Nat Genet 1995;11:441—3.
[64] Biggs PJ, Chapman P, Lakhani SR, Burn J, Stratton MR. The
cylindromatosis gene (cyld1) on chromosome 16q may be the
only tumour suppressor gene involved in the development of
cylindromas. Oncogene 1996;12:1375—7.
[65] Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R,
et al. Identification of the familial cylindromatosis tumour-
suppressor gene. Nat Genet 2000;25:160—5.
[66] Takahashi M, Rapley E, Biggs PJ, Lakhani SR, Cooke D, Hansen
J, et al. Linkage and LOH studies in 19 cylindromatosis families
show no evidence of genetic heterogeneity and refine the CYLD
locus on chromosome 16q12—q13. Hum Genet 2000;106:
58—65.[67] Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of
the cylindromatosis tumour suppressor inhibits apoptosis by
activating NF-kappaB. Nature 2003;424:797—801.
[68] Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach
D, Courtois G. The tumour suppressor CYLD negatively regu-
lates NF-kappaB signalling by deubiquitination. Nature
2003;424: 801—5.
[69] Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ash-
worth A, Mosialos G. CYLD is a deubiquitinating enzyme that
negatively regulates NF-kappaB activation by TNFR family
members. Nature 2003;424:793—6.
[70] Li Q, Verma IM. NF-kappaB regulation in the immune system.
Nat Rev Immunol 2002;2:725—34.
[71] Karin M, Cao Y, Greten FR, Li ZW. NF-kB in cancer: from
innocent bystander to major culprit. Nat Rev Cancer 2002;
2:301—10.
[72] Orlowski RZ, Baldwin Jr AS. NF-kappaB as a therapeutic target
in cancer. Trends Mol Med 2002;8:385—9.
[73] Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the
NF-kappa B transcription factor. Science 1988;242:540—6.
[74] Baeuerle PA, Baltimore D. A 65-kappaD subunit of active NF-
kappaB is required for inhibition of NF-kappaB by I kappaB.
Genes Dev 1989;3:1689—98.
[75] Haskill S, Beg AA, Tompkins SM, Morris JS, Yurochko AD,
Sampson-Johannes A, et al. Characterization of an immedi-
ate-early gene induced in adherent monocytes that encodes I
kappa B-like activity. Cell 1991;65:1281—9.
[76] Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-
kappaB activation. J Biol Chem 1999;274:27339—42.
[77] Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J,
et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases
essential for NF-kappaB activation. Science 1997;278:860—6.
[78] May MJ, Ghosh S. IkappaB kinases: kinsmen with different
crafts. Science 1999;284:271—3.
[79] Karin M. How NF-kB is activated: the role of the IkB kinase (IKK)
complex. Oncogene 1999;18:6867—74.
[80] Smahi A, Courtois G, Rabia SH, Do¨ffinger R, Bodemer C,
Munnich A, et al. The NF-kappaB signalling pathway in human
diseases: from incontinentia pigmenti to ectodermal dyspla-
sias and immune-deficiency syndromes. Hum Mol Genet
2002;11:2371—5.
[81] Fukuda M, Fukuda F, Horiuchi Y, Oku Y, Suzuki S, Kusama K,
et al. Expression of CYLD, NF-kappaB and NF-kappaB-related
factors in salivary gland tumors. In Vivo 2006;20:467—72.
[82] Fukuda M, Hiroi M, Suzuki S, Ohmori Y, Sakashita H. Loss of
CYLD might be associated with development of salivary gland
tumors. Oncol Rep 2008;19:1421—7.
[83] Thomas GJ, Speight PM. Cell adhesion molecules and oral
cancer. Crit Rev Oral Biol Med 2001;12(6):479—98.
[84] Edelman GM, Crossin KL. Cell adhesion molecules: implications
for a molecular histology. Annu Rev Biochem 1991;60:155—90.
[85] He HT, Barbet J, Chaix JC, Goridis C. Phosphatidylinositol is
involved in the membrane attachment of NCAM-120, the
smallest component of the neural cell adhesion molecule.
EMBO J 1986;5:2489—94.
[86] Nybrone O, Bock E. Structure and function of the neural cell
adhesion molecules NCAM and L1. Adv Exp Med Biol 1990;
265:185—96.
[87] Barthels D, Vopper G, Boned A, Cremer H, Wille W. High degree
of NCAM diversity generated by alternative RNA splicing in
brain and muscle. Eur J Neurosci 1992;4:327—37.
[88] Cunningham BA, Hoffman S, Rutishauser U, Hemperly JJ, Edel-
man GM. Molecular topography of the neural cell adhesion
molecule NCAM: surface orientation and location of sialic acid
rich and binding regions. Proc Natl Acad Sci USA 1983;80:
3116—20.
[89] Gennarini G, Hirn M, Deagostini-Bazin H, Goridis C. Studies on
the transmembrane disposition of the neural cell adhesion
The proliferation and progression mechanisms of the oral cancer 39molecule N-CAM. The use of liposome-inserted radioiodinated
N-CAM to study its transbilayer orientation. Eur J Biochem
1984;142:65—73.
[90] Luo J, Miller MW. Transforming growth factor b1-regulated cell
proliferation and expression of Neural Cell Adhesion Molecule
in B104 neuroblastoma cells: differential effects of ethanol. J
Neurochem 1999;72:2286—93.
[91] Einheber S, Hannocks M-J, Metz CN, Rifkin DB, Salzer JL.
Transforming growth factor-b1 regulates Axon/Schwann cell
interactions. J Cell Biol 1995;129:443—58.
[92] Stewart HJS, Rougon G, Dong Z, Dean C, Jessen KR, Mirsky R.
TGF-bs upregulate NCAM and L1 expression in cultured
Schwann cells, suppress cyclic AMP-induced expression of 04
and galactocerebroside, and are widely expressed in cells of
the Schwann cell lineage in vivo. Glia 1995;15:419—36.
[93] Seki H, Koyama K, Tanaka J, Sato Y, Umezawa A. Neural cell
adhesion molecule and perineural invasion in gallbladder can-
cer. J Surg Oncol 1995;58:97—100.
[94] Seki H, Tanaka J, Sato Y, Kato Y, Umezawa A, Koyama K. Neural
cell adhesion molecule (NCAM) and perineural invasion in bile
duct cancer. J Surg Oncol 1993;53:78—83.
[95] Mooy CM, Luyten GP, Jong PT, Jensen OA, Luider TM, van der
Ham F, et al. Neural cell adhesion molecule distribution in
primary and metastatic uveal melanoma. Hum Pathol
1995;26:1185—90.
[96] Gandour-Edwards R, Kapadia SB, Barnes L, Donald PJ, Janecka
IP. Neural cell adhesion molecule in adenoid cystic carcinoma
invading the skull base. Otolaryngol Head Neck Surg 1997;117:
453—8.
[97] Hutcheson JA, Vural E, Korourian S, Hanna E. Neural cell
adhesion molecule expression in adenoid cystic carcinoma
of the head and neck. Laryngoscope 2000;110:946—8.
[98] Franc¸a CM, Jaeger MM, Jaeger RG, Araujo NS. The role of
basement membrane proteins on the expression of neural cell
adhesion molecule (N-CAM) in an adenoid cystic carcinoma cell
line. Oral Oncol 2000;36:248—52.
[99] Fukuda M, Tanaka A, Hamao A, Fukuda F, Kaneko T, Suzuki S,
et al. Expression of neural cell adhesion molecule (NCAM) in
human salivary gland tumor (HSG) cells. Hosp Dent (Tokyo)
2001;13:109—13.
[100] Sporns O, Edelman GM, Crossin KL. The neural cell adhesion
molecule (NCAM) inhibits proliferation in primary cultures of
rat astrocytes. Proc Natl Acad Sci USA 1995;92:542—6.
[101] Krushel LA, Sporns O, Cunningham BA, Crossin KL. Neural cell
adhesion molecule (N-CAM) inhibits astrocyte proliferation
after injury to different regions of the adult rat brain. Proc
Natl Acad Sci USA 1995;92:4323—7.
[102] Fukuda M, Horiuchi Y, Oku Y, Ishikawa M, Suka N, Suzuki S, et al.
Induction of apoptosis in human salivary gland tumor cells by
anti-NCAM antibody. Oncol Rep 2005;14:1143—9.
[103] Jacobson MD, Weil M, Raff MC. Programmed cell death in
animal development. Cell 1997;88:347—54.
[104] Nagata S. Apoptosis by death factor. Cell 1997;88:355—65.
[105] Nagata S, Golstein P. The Fas death factor. Science
1995;267:1449—56.
[106] Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK,
et al. Identification and characterization of a new member of
the TNF family that induces apoptosis. Immunity 1995;3:
673—82.
[107] Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A,
Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new
member of the tumor necrosis factor cytokine family. J Biol
Chem 1996;271:12687—90.
[108] Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth
and induction of apoptotic cell death by the human tumor-
associated antigen RCAS1. Nat Med 1999;5:938—42.
[109] Fukuda M, Tanaka A, Hamao A, Suzuki S, Kusama K, Sakashita
H. Expression of RCAS1 and its function in human squamouscell carcinoma of the oral cavity. Oncol Rep 2004;12:
259—67.
[110] Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B,
et al. Novel p19 protein engages IL-12p40 to form a cyto-
kine, IL-23, with biological activities similar as well as
distinct from IL-12. Immunity 2000;13:715—25.
[111] Sonoda K, Nakashima M, Saito T, Amada S, Kamura T, Nakano H,
et al. Establishment of a new human uterine cervical adeno-
carcinoma cell line, SiSo, and its reactivity to anti-cancer
reagents. Int J Oncol 1995;6:1099—104.
[112] Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H, Wata-
nabe T. A novel tumor-associated antigen expressed in human
uterine and ovarian carcinomas. Cancer 1996;77:1501—9.
[113] Sonoda K, Kaku T, Kamura T, Nakashima M, Watanabe T, Nakano
H. Tumor-associated antigen 22-1-1 expression in the uterine
cervical squamous neoplasias. Clin Cancer Res 1998;4:
1517—20.
[114] Iwasaki T, Nakashima M, Watanabe T, Yamamoto S, Inoue Y,
Yamanaka H, et al. Expression and prognostic significance in
lung cancer of human tumor-associated antigen RCAS1. Int J
Cancer 2000;89:488—93.
[115] Izumi M, Nakanishi Y, Yoshino I, Nakashima M, Watanabe T, Hara
N. Expression of tumor-associated antigen RCAS1 correlates
significantly with poor prognosis in nonsmall cell lung carcino-
ma. Cancer 2001;92:446—51.
[116] Kubokawa M, Nakashima M, Yao T, Ito KI, Harada N, Nawata H,
et al. Aberrant intracellular localization of RCAS1 is associated
with tumor progression of gastric cancer. Int J Oncol
2001;19:695—700.
[117] Noguchi K, Enjoji M, Nakamuta M, Nakashima M, Nishi H, Choi I,
et al. Expression of tumor-associated antigen RCAS1 in hepa-
tocellular carcinoma. Cancer Lett 2001;168:197—202.
[118] Takahashi H, Iizuka H, Nakashima M, Wada T, Asano K, Ishida-
Yamamoto A, et al. RCAS1 antigen is highly expressed in
extramammary Paget’s disease and in advanced stage squa-
mous cell carcinoma of the skin. J Dermatol Sci 2001;26:
140—4.
[119] Hiraoka K, Hida Y, Miyamoto M, Oshikiri T, Suzuoki M, Nakakubo
Y, et al. High expression of tumor-associated antigen RCAS1 in
pancreatic ductal adenocarcinoma is an unfavorable prognos-
tic marker. Int J Cancer 2002;99:418—23.
[120] Nakakubo Y, Hida Y, Miyamoto M, Hashida H, Oshikiri T, Kato K,
et al. The prognostic significance of RCAS1 expression in
squamous cell carcinoma of the oesophagus. Cancer Lett
2002;177:101—5.
[121] Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP,
DuBose RF, et al. Cloning and characterization of TRAIL-R3, a
novel member of the emerging TRAIL receptor family. J Exp
Med 1997;186:1165—70.
[122] Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist
decoy receptor and a death domain-containing receptor for
TRAIL. Science 1997;277:815—8.
[123] Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M,
Baldwin D, et al. Control of TRAIL-induced apoptosis by a
family of signaling and decoy receptors. Science 1997;277:
818—21.
[124] Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M,
Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains
a truncated death domain. Curr Biol 1997;7:1003—6.
[125] Pan G, Ni J, Yu G, Wei YF, Dixit VM. TRUNDD, a new member of
the TRAIL receptor family that antagonizes TRAIL signaling.
FEBS Lett 1998;424:41—5.
[126] Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH,
et al. Functional analysis of TRAIL receptors using monoclonal
antibodies. J immunol 1999;162:2597—605.
[127] Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2
ligand: a novel lethal weapon against malignant glioma? FEBS
Lett 1998;427:124—8.
40 M. Fukuda et al.[128] Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD,
Ashkenazi A. Activation of apoptosis by Apo-2 ligand is inde-
pendent of FADD but blocked by CrmA. Curr Biol 1996;6:750—2.
[129] Fukuda M, Hamao A, Tanaka A, Kitada M, Suzuki S, Kusama K,
et al. Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL/APO2L) and its receptors expression in human squa-
mous cell carcinoma of the oral cavity. Oncol Rep 2003;10(5):
1113—9.
[130] Strand S, Hofmann WJ, Hug H, Mu¨ller M, Otto G, Strand D,
et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas)
ligand-expressing tumor cells: a mechanism of immune eva-
sion? Nat Med 1996;2:1361—6.
[131] Hahne M, Rimoldi D, Schro¨ter M, Romero P, Schreier M, French
LE, et al. Melanoma cell expression of Fas (Apo-1/CD95)
ligand: implications for tumor immune escape. Science
(Washington DC) 1996;274:1363—6.
[132] Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H.
Up-regulation of Fas (APO-1/CD95) ligand and down-regulation
of Fas expression in human esophageal cancer. Cancer Res
1998;58:2057—62.
[133] Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S.
Chemotherapy augments TRAIL-induced apoptosis in breast
cell lines. Cancer Res 1999;59:734—41.
[134] Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla
K. Antileukemic drugs increase death receptor 5 levels and
enhance Apo-2L-induced apoptosis of human acute leukemia
cells. Blood 2000;96:3900—6.
[135] Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ.
Analysis of FasL and TRAIL induced apoptosis pathways in
glioma cells. Oncogene 2001;20:5789—98.
[136] Pai SI, Wu GS, O¨zo¨ren N, Wu L, Jen J, Sidransky D, et al. Rare
loss-of-function mutation of a death receptor gene in head and
neck cancer. Cancer Res 1998;58:3513—8.
[137] Fisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, Powell SM,
et al. Nucleotide substitution in the Ectodomain of TRAIL
receptor DR4 is associated with lung cancer and head and
neck cancer. Clin Cancer Res 2001;7:1688—97.
[138] Scaffidi C, Kirchhoff S, Krammer PH, Peter ME. Apoptosis
signaling in lymphocytes. Curr Opin Immunol 1999;11:277—85.
[139] Nakamura M, Rieger J, Weller M, Kim J, Kleihues P, Ohgaki H,
et al. Expression in human brain tumors. Acta Neuropathol
2000;99:1—6.
[140] Matsuzaki H, Schmied BM, Ulrich A, Standop J, Schneider MB,
Batra SK, et al. Combination of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) and actinomycin D induces
apoptosis even in TRAIL-resistant human pancreatic cancer
cells. Clin Cancer Res 2001;7:407—14.
[141] Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P,
Schlossman R, et al. TRAIL/Apo2L ligand selectively induces
apoptosis and overcomes drug resistance in multiple myeloma:
therapeutic applications. Blood 2001;98:795—804.
[142] Balkwill F, Mantovani A. Inflammation and cancer: back to
Virchow? Lancet 2001;357:539—45.
[143] Coussens LM, Werb Z. Inflammation and cancer. Nature
2002;420:860—7.
[144] Balkwill F, Charles KA, Mantovani A. Smoldering and polarized
inflammation in the initiation and promotion of malignant
disease. Cancer Cell 2005;7:211—7.
[145] Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo
AM. Cyclooxygenases in cancer: progress and perspective.
Cancer Lett 2004;215:1—20.
[146] Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K,
et al. IL-23 promotes tumour incidence and growth. Nature
2006;27:461—5.
[147] Sospedra M, Martin R. Immunology of multiple sclerosis. Annu
Rev Immunol 2005;23:683—747.
[148] Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J,
et al. A receptor for the heterodimeric cytokine IL-23 iscomposed of IL-12Rbeta1 and a novel cytokine receptor sub-
unit, IL-23R. J Immunol 2002;168:5699—708.
[149] Lankford CSR, Frucht DM. A unique role for IL-23 in promoting
cellular immunity. J Leukoc Biol 2003;73:49—56.
[150] Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR,
Murphy M, et al. Antitumor and antimetastatic activity of
interleukin 12 against murine tumors. J Exp Med 1993;178:
1223—30.
[151] Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA,
Brunda MJ, et al. Recombinant IL-12 administration induces
tumor regression in association with IFN-production. J Immu-
nol 1994;153:1697—706.
[152] Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B,
et al. Interleukin-23 rather than interleukin-12 is the critical
cytokine for autoimmune inflammation of the brain. Nature
2003;421:744—8.
[153] Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan
T, Kastelein RA, et al. Divergent pro- and anti-inflammatory
roles for IL-23 and IL-12 in joint auto-immune inflammation.
J Exp Med 2003;198:1951—7.
[154] Becher B, Durell BG, Noelle RJ. IL-23 produced by CNSresident
cells controls T cell encephalitogenicity during the effector
phase of experimental autoimmune encephalomyelitis. J Clin
Invest 2003;112:1186—91.
[155] Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM. In vitro
and in situ expression of IL-23 by keratinocytes in healthy skin
and psoriasis lesions: enhanced expression in psoriatic skin.
J Immunol 2006;176:1908—15.
[156] Fukuda M, Ehara M, Suzuki S, Sakashita H. Expression of
interleukin-23 and its receptors in human squamous cell car-
cinoma of the oral cavity. Mol Med Rep 2010;3:89—93.
[157] Fukuda M, Ehara M, Suzuki S, Ohmori Y, Sakashita H. IL-23
promotes growth and proliferation in human squamous cell
carcinoma of the oral cavity. Int J Oncol 2010;36:1355—65.
[158] Kusama K, Fukuda M, Kikuchi K, Ishikawa M, Sakashita H,
Nemoto N, et al. Dendritic cells and oral cancer (Review).
J Oral Biosci 2005;47(1):42—51.
[159] Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL,
Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene
expression in solid tumors and influences both angiogenesis
and tumor growth. Proc Natl Acad Sci USA 1997;94:8104—9.
[160] Ryan HE, Lo J, Johnson RS. HIF-1a is required for solid tumor
formation and embryonic vascularization. EMBO J 1998;
17:3005—15.
[161] Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible
factor-1 is a basic-helix-loop-helix-PAS heterodimer regulat-
ed by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:
5510—4.
[162] Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P,
et al. Transcription factor HIF-1 is a necessary mediator of the
pasteur effect in mammalian cells. Mol Cell Biol 2001;21(10):
3436—44.
[163] Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of
hypoxia-inducible transcription factor depends primarily upon
redox-sensitive stabilization of its alpha subunit. J Biol Chem
1996;271:32253—9.
[164] Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D,
Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced
degradation of hypoxia-inducible factor 1 alpha. Genes Dev
2000;14:34—44.
[165] Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC,
Cockman ME, et al. The tumour suppressor protein VHL targets
hypoxia-inducible factors for oxygen-dependent proteolysis.
Nature 1999;399:271—5.
[166] Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA,
Bauer C, et al. HIF-1 is expressed in normoxic tissue and
displays an organ-specific regulation under systemic hypoxia.
FASEB J 2001;15:2445—53.
The proliferation and progression mechanisms of the oral cancer 41[167] Wang GL, Semenza GL. General involvement of hypoxia-induc-
ible factor 1 in transcriptional response to hypoxia. Proc Natl
Acad Sci USA 1993;90:4304—8.
[168] Wang GL, Semenza GL. Purification and characterization of
hypoxia-inducible factor 1. J Biol Chem 1995;270:1230—7.
[169] Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J,
et al. Constitutive expression of hypoxia-inducible factor-
1alpha renders pancreatic cancer cells resistant to apoptosis
induced by hypoxia and nutrient deprivation. Cancer Res
2001;61(17):6548—54.
[170] Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K,
Dewerchin M, et al. Role of HIF-1a in hypoxia-mediated apo-
ptosis, cell proliferation and tumour angiogenesis. Nature
1998;394:485—90.
[171] An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV,
Neckers LM. Stabilization of wild-type p53 by hypoxia-induc-
ible factor 1a. Nature 1998;392:405—8.
[172] Birner P, Schindl M, Obermair A, Plank C, Breitenecker G,
Oberhuber G. Overexpression of hypoxia-inducible factor 1a
is a marker for an unfavorable prognosis in early-stage invasive
cervical cancer. Cancer Res 2000;60:4693—6.
[173] Kuwai T, Kitadai Y, Tanaka S, Onogawa S, Matsutani N, Kaio E,
et al. Expression of hypoxia-inducible factor-1a is associated
with tumor vascularization in human colorectal carcinoma. Int
J Cancer 2003;105(2):176—81.
[174] Graeber TG, Peterson JF, Tsai M, Monica K,Fornace Jr AJ, Giaccia
AJ. Hypoxia induces accumulation of p53 protein, but activation
of a G1-phase checkpoint by low-oxygen conditions is indepen-
dent of p53 status. Mol Cell Biol 1994;14(9):6264—77.
[175] Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe
SW, et al. Hypoxia-mediated selection of cells with diminished
apoptotic potential in solid tumours. Nature 1996;379(6560):
88—91.
[176] Fukuda M, Sakashita H. Expression of hypoxia-inducible factor-
1a in squamous cell carcinoma of the oral cavity. Hosp Dent
(Tokyo) 2010;21(2):85—90.
[177] Freston JW, Cimetidine I. Developments, pharmacology, and
efficacy. Ann Intern Med 1982;97:573—80.
[178] Burtin C, Noirot C, Scheinmann P, Galoppin L, Sabolovic D,
Bernard P. Clinical improvement in advanced cancer disease
after treatment combining histamine and H2-anti-histaminics
(ranitidine or cimetidine). Eur J Cancer Clin Oncol 1988;24:
161—7.
[179] Siegers CP, Andresen S, Keogh JP. Does cimetidine improve
prospects for cancer patients? A reappraisal of the evidence to
date. Digestion 1999;60:415—21.[180] Tønnesen H, Knigge U, Bu¨low S, Damm P, Fischerman K,
Hesselfeldt P, et al. Effect of cimetidine on survival after
gastric cancer. Lancet 1988;2:990—2.
[181] Adams WJ, Lawson JA, Morris DL. Cimetidine inhibits in vivo
growth of human colon cancer and reverses histamine stimu-
lated in vitro and in vivo growth. Gut 1994;35:1632—6.
[182] Hansbrough JF, Zapata-Sirvent RL, Bender EM. Prevention
of alterations in postoperative lymphocyte subpopulations
by cimetidine and ibuprofen. Am J Surg 1986;151:
249—55.
[183] Adams WJ, Morris DL, Ross WR, Lubowski DZ, King DW. Cimeti-
dine preserves non-specific immune function after colonic
resection for cancer. Aust N Z J Surg 1994;64:847—52.
[184] Sasson AR, Gamagami R, An Z, Wang X, Moossa AR, Hoffman
RM. Cimetidine: an inhibitor or promoter of tumor growth? Int
J Cancer 1999;81:835—8.
[185] Lawson JA, Adams WJ, Morris DL. Ranitidine and cimetidine
differ in their in vitro and in vivo effects on human colonic
cancer growth. Br J Cancer 1996;73:872—6.
[186] Reynolds JL, Akhter J, Morris DL. In vitro effect of histamine
and histamine HI and H2 receptor antagonists on cellular
proliferation of human malignant melanoma cell lines. Mela-
noma Res 1996;6:95—9.
[187] Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T.
Cimetidine inhibits cancer cell adhesion to endothelial cells
and prevents metastasis by blocking E-selectin expression.
Cancer Res 2000;60:3978—84.
[188] Fukuda M, Tanaka S, Suzuki S, Kusama K, Kaneko T, Sakashita H.
Cimetidine induces apoptosis of human salivary gland tumor
cells. Oncol Rep 2007;17(3):673—8.
[189] Simpson CS, Morris BJ. Regulation of neuronal cell adhesion
molecule expression by NF-kappa B. J Biol Chem 2000;275:
16879—84.
[190] Krushel LA, Cunningham BA, Edelman GM, Crossin KL. NF-
kappaB activity is induced by neural cell adhesion molecule
binding to neurons and astrocytes. J Biol Chem 1999;
274:2432—9.
[191] Fukuda M, Kusama K, Sakashita H. Cimetidine inhibits salivary
gland tumor cell adhesion to neural cells and induces apoptosis
by blocking NCAM expression. BMC Cancer 2008;8:8—376
[Available online 18 December 2008 from doi:10.1186/1471-
2407-376].
[192] Sudha K, Zhihong D, Dmitry V, Atsushi I, Helman JI, Prince ME,
et al. Endothelial cell-initiated signaling promotes the survival
and self-renewal of cancer stem cells. Cancer Res 2010;70(23):
9969—78.
